Bevacizumab, a vascular endothelial growth factor (VEGF)-targeting drug, is widely used as an off-label therapeutic for age-related macular degeneration (AMD). To reduce the monthly administration frequency, this study investigated microspheres comprising a poly(D, L-lactide-co-glycolide)/poly(cyclohexane-1,4-diyl acetone dimethylene ketal) (PLGA/PCADK) blend that could be loaded with bevacizumab-dextran particles using solidin-oil-in-water (S/O/W) emulsification. Control microspheres were also prepared through water-in-oil-in-water (W/O/W) emulsification. The structural stability of bevacizumab in the polymer monomers was analyzed using dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), size exclusion chromatography (SEC-HPLC), circular dichroism (CD) and fluorescence spectroscopy. Subsequently, microspheres were prepared and evaluated in terms of their morphology, encapsulation efficiency and release behavior. PLGA/PCADK microspheres prepared by the S/O/W method with < 20% PCADK showed a smooth spherical structure with a uniform distribution of bevacizumab. The microspheres exhibited a release behavior comprising a slight initial burst and an increasing total release over 50 days both in vitro and in vivo. Additionally, the microspheres were well tolerated by ocular tissue. Finally, a chorioallantoic membrane (CAM) assay revealed that the bioactivity of bevacizumab was retained by PCADK. In conclusion, these results suggest the potential for bevacizumab-loaded PLGA/PCADK microspheres prepared by the S/O/W method as a means of intravitreal therapy for ocular diseases.
Introduction
Bevacizumab (Avastin®, Genentech/Roche), a 149 kDa humanized monoclonal IgG antibody against vascular endothelial growth factor (VEGF), inhibits angiogenesis (Michels et al., 2005) and was first approved for systemic use in the treatment of metastatic colorectal cancer in 2004 by the Food and Drug Administration (FDA) (Ellis, 2005) . However, bevacizumab is also widely used as an off-label intravitreal therapy for severe ocular diseases such as age-related macular degeneration (AMD), the main cause of blindness in the elderly (Avery et al., 2006; Gower et al., 2017; Grassmann et al., 2015; Michels et al., 2005) . This drug has a short intravitreal half-life of only 3-5 days, thus necessitating monthly injections to maintain a therapeutically effective drug concentration (Veurink et al., 2011) . These relatively frequent intravitreal administrations are invasive, highly inconvenient for patients and increase the risk of complications, such as intraocular inflammation, subconjunctival hemorrhage and chemosis, and retinal pigment epithelial detachment (Angkawinitwong et al., 2017; Sampat and Garg, 2010) . Accordingly, the development of a sustained-release form of bevacizumab, which would reduce the need for repeated injections, is a universal goal.
Polymeric microspheres allow the sustained release of a drug over a long period of time and have thus been proposed as a carrier for local drug delivery (Bitencourt et al., 2015) . Currently, the simple and rapid water-in-oil-in-water (W/O/W) multiple emulsion-solvent evaporation technique is often used to formulate polymeric microspheres (Silva et al., 2016) . However, this method has several drawbacks with respect to bevacizumab. For example, the oil-water interface can potentially destroy bevacizumab during encapsulation into the oil phase to form the primary emulsion (Stenekes et al., 1999; Yuan et al., 2007) . Furthermore, bevacizumab can easily diffuse from the internal to the external water phase during the fabrication process. This would distribute the drug over the microsphere surface, which would likely cause a remarkable initial burst of drug release followed by the development of pores or channels (Utzinger et al., 2017) . Therefore, a modified solid-inoil-in-water (S/O/W) method has been proposed to protect the structural stability of bevacizumab while reducing the initial burst. Furthermore, the bioactivity of bevacizumab can be protected by initially microencapsulating the drug into dextran particles without exposure to a water-oil interface (Breen et al., 2001) .
To date, microspheres fabricated using the FDA-approved material poly (D, L-lactide-co-glycolide) (PLGA) have exhibited excellent encapsulation of therapeutic proteins/peptides and long-acting behavior, leading to PLGA receiving a considerable amount of medical and pharmaceutical attention. Despite the good biodegradability and biocompatibility of PLGA microspheres, however Fornaguera et al., 2016; Liu et al., 2017; Qiao et al., 2016; Sun et al., 2017) , the effective encapsulation of protein drugs into this polymer matrix remains challenging. Specifically, PLGA degradation causes lactic acid (LA) and glycolic acid (GA) to accumulate inside the microspheres, and the resulting decrease in the microenvironmental pH causes protein drugs aggregate, degrade and denature. Additionally, the acidic environment within the microspheres can cause ocular inflammatory reactions and other toxic responses that are associated with various complications.
To overcome the above-described issues, poly(cyclohexane-1, 4-diyl acetone dimethylene ketal) (PCADK) is a type of polyketal. This novel acid-degradable polymer can be synthesized via an acetal exchange reaction between 1,4-cyclohexanedimethanol (1,4-CHDM) and 2,2-dimethoxypropane, which have ketal linkages in their backbones. Both monomers are neutral compounds that do not exhibit rapid decreases in pH outside of acidic environments (Wang et al., 2015) . Accordingly, this study aimed to develop a PLGA/PCADK composite microsphere formulation using the S/O/W emulsion-solvent evaporation technique in an attempt to protect both bevacizumab and eyes from damage. The properties of the microspheres loaded with bevacizumab-dextran particles were evaluated through studies of their surface morphology, encapsulation efficiency, differential scanning calorimetry (DSC), intramicrospheric bevacizumab distribution, in vitro and in vivo drug release, immunohistochemistry and a chick embryo chorioallantoic membrane (CAM) assay.
Materials and methods

Materials
LA (85-90%, analytical reagent (AR) grade), acetone (> 99.5%, AR), disodium hydrogen phosphate dodecahydrate (> 99%, AR), hydrochloric acid (36-68%, AR) and dichloromethane (> 99.5%, AR) were purchased from Beijing Chemical Works (Beijing, China). GA (> 98%) and 1,4-CHDM (> 99%) were purchased from Aladdin Chemistry Co., Ltd. (Shanghai, China). Fluorescein isothiocyanate (FITC) was purchased from Boyao Biotechnology Co., Ltd. (Shanghai, China). Polyvinyl alcohol (PVA, 87-89% hydrolyzed, molecular weight (Mw) 13,000-23,000 Da), polyethylene glycol (PEG) (Mw 8000) and dextran (Mw 64,000-76,000) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Bevacizumab (Mw 149 kDa) and PLGA polymers (7525 4A) were donated by Luye Pharmaceutical Co., Ltd. (Shandong, China). All other chemicals were of analytical grade and used without further purification.
Preparation of bevacizumab-loaded dextran particles
Bevacizumab-dextran particles were prepared by vortex mixing bevacizumab (0.15% w/v), dextran (0.45% w/v) and PEG (8% w/v) for 5 min. The mixture was subsequently lyophilized using a lyophilizer (ALPHA 1-2 LD PLUS, Christ, Osterode am Harz, Germany) for 24 h. The reclaimed lyophilized powders were washed with dichloromethane to remove the PEG dispersion phase and dried in a vacuum dryer.
2.3. Effect of PCADK monomers on the structural stability of bevacizumab and bevacizumab-dextran particles Bevacizumab and bevacizumab-dextran particles were incubated with PCADK monomers to monitor the effect of the latter on the structural stability of the former. A mixed aqueous solution of acetone and 1,4-CHDM was used to represent PCADK monomers, while a mixed aqueous solution of LA and GA was used to represent PLGA monomers. The concentration of each monomer was set as 0.08 mol/L. All solutions were passed through a filter with a 0.22-μm pore size. Bevacizumab and bevacizumab-dextran particles were diluted to a bevacizumab concentration of 0.4 mg/mL in the above solutions. After a 21-day incubation period at 37°C, all samples were taken out for further testing.
The structural integrity of bevacizumab was analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion chromatography (SEC-HPLC). Circular dichroism (CD) (J-810, Jasco, USA) was used to evaluate the secondary structures of the bevacizumab samples. The spectral wavelength range was 190 to 260 nm and collected with a 0.1 cm quartz cell at 25°C (Sousa et al., 2017) . To confirm the states of the tertiary structures, fluorescence spectra were collected on a Shimadzu RF-5301 instrument over an emission spectrum of 305-550 nm and an excitation wavelength of 280 nm (Determan et al., 2006) .
Preparation of microspheres using the S/O/W emulsion-solvent evaporation method
Bevacizumab was encapsulated in the microspheres according to a modified S/O/W emulsion-solvent evaporation method. The dried, bevacizumab-loaded dextran particles were emulsified in a methylene chloride solution containing 100 mg (total weight) of PLGA/PCADK at different ratios, using an ultrasonic processor at 4 W for 60 s in an ice bath. Then, the stabilized suspension was added dropwise into a 10 mL solution of PVA in deionized water (2% w/v), homogenized at 5000 rpm for 2 min at 4°C, immediately poured into 100 mL of 0.5% (w/v) PVA and stirred gently for no less than 3 h using a magnetic stirrer (KIKA, German). After three washes with deionized water, the hardened microspheres were lyophilized.
Preparation of microspheres using the W/O/W emulsion-solvent evaporation method
For comparison, microspheres were also prepared using the W/O/W method. A bevacizumab solution was added to a methylene chloride solution containing PLGA/PCADK (total composite polymer weight = 100 mg) and homogenized at 3000 rpm for 2 min on ice. Then, the stabilized suspension was added dropwise into a 10 mL solution of PVA in deionized water (2% w/v), homogenized at 5000 rpm for 2 min at 4°C, immediately transferred into 100 mL of 0.5% (w/v) PVA and stirred gently for no less than 3 h. The hardened microspheres were washed with deionized water and lyophilized.
2.6. Surface morphology of bevacizumab-dextran particles and bevacizumab-loaded PLGA/PCADK microspheres Scanning electron microscopy (SEM) was used to evaluate the surface morphology of the bevacizumab-dextran particles and bevacizumab-loaded PLGA/PCADK microspheres. The samples were mounted onto the surfaces of sample holders using a double-sided adhesive and coated with gold under a vacuum. The SEM images were obtained using a JXA-840 system (JEOL, Tokyo, Japan) at an electron beam energy of 3 kV.
Efficiency of bevacizumab encapsulation into the microspheres
The efficiency of bevacizumab encapsulation into the microspheres was determined using a micro bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Briefly, 10 mg of the bevacizumab-loaded microspheres were dispersed in 1 mL of an aqueous NaOH solution (1 M) to dissolve the PLGA in the microspheres. Subsequently, 2 mL of an aqueous HCl solution (1 M) was added to degrade PCADK. Then, NaOH solution was added to neutralize the pH of the solution. Finally, the recovered bevacizumab content in the solution was measured using the micro BCA assay.
In vitro release of bevacizumab from the microspheres
Briefly, 10 mg of each batch of bevacizumab microspheres was collected in a microtube and suspended in 2 mL of 20 mM PBS. The microtubes were then placed in an orbital shaking incubator at 37°C and a rotation speed of 110 rpm. At predetermined time intervals, 1 mL of the supernatant solution was withdrawn and replaced with an equal volume of fresh buffer. The amount of released bevacizumab was determined using the micro BCA protein assay kit described in Section 2.7.
DSC analysis of the microspheres
The thermographic characteristics of selected batches of bevacizumab-loaded PLGA/PCADK microspheres, bevacizumab-dextran particles and the components were determined using DSC (DSC 1; Mettler Toledo, Zürich, Switzerland). An approximately 5 mg sample was tested in an aluminum pan under pure dry nitrogen at a flow rate of 20 mL/min. Thermograms for bevacizumab, dextran, bevacizumabdextran particles, PLGA, PCADK and the bevacizumab-loaded PLGA/ PCADK microspheres were obtained while increasing the temperature from 25 to 200°C at a scanning rate of 10°C/min.
Distribution of bevacizumab within the bevacizumab-dextran particles and the bevacizumab-loaded PLGA/PCADK microspheres
The dextran particles and the PLGA/PCADK microspheres were loaded with bevacizumab-FITC according to the S/O/W emulsion-solvent evaporation method described in Sections 2.2-2.4. Subsequently, a suspension of the particles in ethanol or a suspension of the microspheres in deionized water was dropwise added onto a glass slide and covered. The bevacizumab distribution within the particles and the microspheres was evaluated using a laser scanning confocal microscope (LSM 710, Carl Zeiss, Oberkochen, Germany) with set excitation and emission wavelengths of 488 and 525 nm, respectively. Images are shown as ortho reconstruction of z-stacks.
2.11. Animal experiments 2.11.1. Animal source Male New Zealand White rabbits (body weight: ∼2.0 kg, n = 3 per group for each time point) were used in animal experiments that were approved by the Experimental Animal Ethics Committee of the School of Life Sciences, Jilin University. All rabbits were cared for and treated in accordance with the Association for Research in Vision and Ophthalmology (ARVO) resolution concerning the use of animals in ophthalmological research. Prior to treatment, all animals were free from ocular diseases.
Prior to intravitreal injection, the rabbits were anesthetized via a subcutaneous injection (3.5 mL/kg body weight) of 10% chloral hydrate, with the separate administration of Alcaine® and Mydriacyl® (both Alcon Laboratories Ltd., Fort Worth, TX, USA) to the eyes of the rabbits for topical anesthesia and mydriasis, respectively 2.11.2. In vivo release of bevacizumab from the microspheres Briefly, the rabbits were divided into three groups of 21 rabbits each. The groups corresponded to specific time points. One group was intravitreally injected with 100 μL of bevacizumab solution (final bevacizumab dosage = 0.4 mg). The other two groups were intravitreally injected with bevacizumab microspheres (PLGA microspheres and PLGA/PCADK microspheres) to yield the same final bevacizumab dosage. At specific time points (1 and 4 days and 1, 2, 4, 6 and 8 weeks after injection), the rabbits were sacrificed. Samples of the cornea, aqueous humor, choroid and sclera, vitreous and retina were collected and subjected to quantitative determination of bevacizumab using an enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA).
Intraocular pressure (IOP) measurement
To assess the potential effects of intravitreal microspheres on the IOP, this parameter was measured using a tonometer (Icare®; TONOVET, Vantaa, Finland) prior to injection and at each time point indicated for sacrifice (Swaminathan et al., 2014) . The average of six consecutive readings was considered for analysis.
Ocular irritation test
Ocular irritation associated with the microspheres was evaluated by intravitreally injecting 100 μL of blank microspheres (or saline as a negative control) into the eyes of rabbits. Congestion, swelling and redness of the eyes was observed. At 1 week after the intravitreal injection, the rabbit eyes were enucleated and fixed in 4% paraformaldehyde overnight at 4°C to enable a histological evaluation (Miyake et al., 2010) . After fixed, the eyes were embedded in paraffin, cut into 10-μm-thick sections and stained with hematoxylin and eosin (H&E) prior to histological observation of the retinas. A light microscope (Nikon Instruments Inc., Tokyo, Japan) at 200x magnification was used to examine the slides.
In vivo antiangiogenic studies
A CAM assay was used to evaluate the effect of the bevacizumab released from the PLGA and PLGA/PCADK microspheres on angiogenesis in vivo. Briefly, 20 fertilized chicken eggs per group were incubated at 60% to 70% relative humidity and a temperature of 37°C. On day 4 of embryonic development, a small window (diameter: ∼10 mm) into the air chamber of each egg was created. The bevacizumab released solution was diluted to 100 μg/mL with PBS to adjust the concentration prior to testing drug's activity. Twenty microliters of a 100 μg/mL drug solution were mixed with a 0.5% solution of methylcellulose in water and dried to form a disc with a diameter of approximately 2 mm. The original 100 μg/mL bevacizumab solution was selected as a positive control. On day 6 of embryonic development, a drug-containing disc was gently implanted into each CAM via the window. On the 8th day of incubation, the CAMs were fixed with 3.7% formaldehyde in PBS and photographed. The number of blood vessels in each CAM was counted. For blood vessel quantification, the value of the negative control group (saline) was set at 100%.
Statistical analysis
All data are presented as mean values ± standard deviations. Statistical analysis among groups was conducted using One-way analysis of variance (ANOVA). A p value < 0.05 was considered to indicate a significant difference.
Results and discussion
3.1. Effect of the PCADK monomers on the structural stability of bevacizumab and bevacizumab-dextran particles
The structural integrity of bevacizumab and bevacizumab-dextran particles were evaluated using SEC-HPLC. After a 21-day incubation period of bevacizumab with the PCADK monomers, a peak corresponding to bevacizumab appeared after approximately 17 min and an additional broad peak appeared at 11-16 min as shown in Fig. 1a . However, two broad peaks appeared at 11-18 min and 25-29 min in the PLGA group. Peak area calculations revealed that more than 80% of the initially added bevacizumab was recovered from the PCADK monomers after 21 days, compared to a 16% recovery from the PLGA monomers (data not shown). After a 21 day incubation period of bevacizumab-dextran particles with the PBS, PCADK monomers and PLGA monomers, the peaks appeared similar to that of bevacizumabdextran particles with solutios above. Peak area calculations revealed that more than 90% of the initially added bevacizumab was recovered from the PCADK monomers after 21 days, compared to a 54% recovery from the PLGA monomers (data not shown). This finding indicated that bevacizumab formed aggregates and degraded during incubation with the PLGA monomers but retained its structural integrity better when incubated with the PCADK monomers. The structure integrity of bevacizumab microencapsulated in the dextran particles can be protected further by resisting to organic solvent (Breen et al., 2001) .
The SDS-PAGE results (Fig. 1b) showed that the PCADK monomers yielded bevacizumab bands more similar to those in the PBS group than PLGA monomers. Additionally, bevacizumab-dextran particles bands appeared more integrated. Fewer fragmented bands were detected in the bevacizumab-dextran particles of all their groups, consistent with the SEC-HPLC chromatogram data.
The secondary structures were determined using CD (Fig. 1c) . Bevacizumab yielded a single CD curve at about 212 nm. The CD signal intensity of bevacizumab incubated with PCADK monomers was nearly identical to that of the PBS-incubated drug, whereas the intensity of bevacizumab incubated with PLGA monomers was very different. Similarly, bevacizumab with dextran particles showed better stability of the secondary structure. Accordingly, the results suggested that the PCADK monomers and dextran particles could better maintain the secondary structure of bevacizumab. Fig. 1d presents the fluorescence spectra of bevacizumab incubated under various conditions. Notably, the fluorescence intensity of the drug incubated with the PLGA products was visibly different from those incubated with PBS and the PCADK products, indicating a change in the tertiary structure in the former. The instability of bevacizumab in the PLGA group was attributed to the acidic environment induced by LA and GA. Also, bevacizumab with dextran particles seemed to be better. 
Bevacizumab-loaded PLGA/PCADK microspheres
Because bevacizumab was shown to be much more stable upon exposure to the monomers of PCADK rather than those of PLGA, PCADK was added to the microspheres. As shown in Table 1 , microspheres containing different ratios of PCADK and PLGA were prepared using the S/O/W emulsion-solvent evaporation or W/O/W emulsion-solvent evaporation method. Microspheres prepared using the W/O/W method generally exhibited a spherical shape and smooth surface in the absence of PCADK (Fig. 2b) but developed a rough surface with holes as the amount of PCADK increased ( Fig. 2c and d) . Additionally, the encapsulation efficiency decreased significantly from 37.85 ± 0.48% to 21.01 ± 0.96% as the PCADK proportion increased from 0% to 50%.
For the S/O/W method, the initially prepared bevacizumab-dextran particles had diameters of 1-2 μm (Fig. 2a) and exhibited a spherical shape and smooth surface. This particle size was acceptable for the inner layer of a microsphere with a final diameter of 5-30 μm. Subsequently, encapsulation efficiency values of 47.18 ± 0.84%, 46.46 ± 0.48% and 33.85 ± 0.61% were observed for PCADK proportions of 0%, 20% and 50%, respectively. The decrease in efficiency may be attributable to the development of surface irregularities and porosity in the particles with the highest amount of PCADK.
In a comparison of PLGA/PCADK microspheres containing 20% PCADK, those prepared using the S/O/W method were formed without holes (Fig. 2f) , whereas those prepared using the W/O/W method were porous (Fig. 2c) . As noted in the Introduction, this result may be attributable to diffusion of the internal and external water phases during the W/O/W preparation process. The diffusion of the water phase also decreases the encapsulation efficiency. Therefore, the S/O/W preparation method appeared to be conducive to improving drug loading and yielded a more complete spherical shape. The above results demonstrate the effects of the PCADK content on the morphology and encapsulation efficiency. PCADK has a low molecular weight and poor mechanical properties, thus, PLGA plays a major role in the composite microspheres. As the content of PCADK was increased, there were problems with poor spherical formation and more debris and holes appearing on the surface of the microspheres, leading to leakage of the protein. Accordingly, we concluded that microspheres containing 20% PCADK prepared using the S/O/W method and exhibited an excellent morphology and encapsulation efficiency.
In vitro release of bevacizumab from the microspheres
The release of bevacizumab from microspheres prepared using the W/O/W or S/O/W method was detected at 37°C over a 50-day period (Fig. 3) . Within the initial 1 h, the bevacizumab release rates were 20.1% and 20.9% for microspheres containing 0% and 20% PCADK that were prepared using the W/O/W method and 9.6% and 9.3% for microspheres containing 0% and 20% PCADK that were prepared using J. Liu, et al. International Journal of Pharmaceutics 563 (2019) 228-236 the S/O/W method, respectively. It was possible that the microspheres prepared using the W/O/W method exhibited a stronger initial burst release, which may be attributable to the diffusion of the internal and external water phases during the preparation process and the resulting deposition of bevacizumab on the surface of the microspheres. Additionally, microspheres prepared using the S/O/W method exhibited steady sustained-release behavior during the 50 day observation. The cumulative release of bevacizumab from microspheres containing 0% and 20% PCADK prepared using the W/O/W and S/O/W methods were approximately 43.5%, 50.0%, 59.6% and 75.7% after 50 days, respectively. PLGA/PCADK microspheres prepared using the S/O/W method provided a key advantage, namely that their minimal initial burst release and total steady sustained-release are helpful for producing a therapeutic window and reducing the drug administration frequency.
DSC of the microspheres
According to the DSC spectra (Fig. 4) , the melting peaks of PCADK appeared at 105 and 140°C, whereas the peak of PLGA appeared at approximately 55°C. The melting peak of bevacizumab appeared at approximately 120°C. The melting peak of dextran appeared at approximately 115°C. The DSC spectrum of microspheres prepared from a combination of PLGA and PCADK prepared by both methods yielded three peaks at 55, 105 and 140°C, indicating that the PLGA/PCADK microspheres were produced from the physical mixing of PLGA and PCADK, with no thermal property changes between these components. The lack of a peak at 120°C of bevacizumab and 115°C of dextran proved that bevacizumab was entrapped and not present on the surface of the microspheres.
Bevacizumab distribution within the bevacizumab-dextran particles and the bevacizumab-loaded PLGA/PCADK microspheres
Bevacizumab-FITC emits a bright yellow-green fluorescent signal when excited at 488 nm. We used confocal scanning laser tomography to observe the FITC fluorescence intensity and thus the distribution of bevacizumab within the particles or the microspheres. As shown in Fig. 5a , fluorescence was detected in all the scanned microspheres, and no apparent light or dark areas were observed on the periphery or inside of the microspheres. In other words, bevacizumab was nearly uniformly distributed in the particles. As show in Fig. 5b , the center of bevacizumab-loaded microspheres was clearly darker than the surrounding part as the scanning depth increased. This result implied that the drug was concentrated close to the periphery of the microspheres because the microspheres were prepared using the W/O/W double emulsion method, during which the permeation of inner bevacizumab phase to external water phase brings bevacizumab IgG closer to the microsphere surface (Lee et al., 2010) . Obviously, bevacizumab was nearly uniformly distributed in the microspheres prepared using the S/ O/W emulsion-solvent evaporation method (Fig. 5c) , during which the permeation of inner particles to external water phase was poor because of the low solubility of dextran in cold water. This drug distribution ensured a sustained and constant drug release rate without an obvious sudden release or delay, which was consistent with the in vitro release behavior described in Section 3.3.
In vivo release of bevacizumab from the microspheres
Next, the pharmacokinetics and intra-eye movement of an intravitreally injected bevacizumab solution, bevacizumab PLGA microspheres and bevacizumab PLGA/PCADK microspheres were compared. The concentrations of bevacizumab in various eye tissues were detected in the following descending order: vitreous > retina > aqueous humor > cornea > choroidal and sclera. Fig. 6 presents a concentration (ng/mg tissue)-time profile for the critical eye tissues over an 8-week period. The release behavior of bevacizumab in the retina was similar to that in the vitreous humor, although a much lower concentration was detected in the former.
AUC ∞ values were calculated using DAS 3.0 software (Drug and Statistics Software, Mathematical Pharmacology Professional Committee of China, Shanghai, China). The highest AUC ∞ was calculated for the vitreous (226,002.59 d ng/mg from PLGA microspheres (Xie et al., 2015) . Much lower bevacizumab concentrations were observed in the cornea and choroidal sclera. For all the listed eye tissues, the one-way ANOVA showed a significant difference in bevacizumab concentrations between the rabbits treated with the bevacizumab solution and those administered bevacizumab-loaded microspheres. Furthermore, the AUC ∞ of bevacizumab from PLGA/PCADK microspheres was larger than that from PLGA microspheres. These in vivo release results were consistent with the in vitro release findings, suggesting that the addition of PCADK effectively increased the bioavailability of bevacizumab. The longer retention time in eye tissues could be explained by the unique composition of non-enzymatic collagen, resulting in the slow clearance of bevacizumab. 
IOP measurement
Ocular irritation test
The potential irritability of blank PLGA/PCADK or PLGA microspheres was assessed via intravitreal injection. Notably, no undesirable effects, such as congestion, swelling and redness, were observed (Fig. 8) . Potential retinal damage was further investigated by histological analysis. The entire retinal tissues from all tested groups exhibited a normal morphology and architecture at 1 week post-injection, no macrophage infiltration, edema, or swelling was found in the eyes, and the thicknesses of the cell layers for the experimental groups were similar to that of the control group, but some inflammatory cells (marked with red arrows in Fig. 8d ) appeared in tissue samples from the PLGA microsphere group. We speculated that the acidic environment induced by PLGA aggravated the eyes and induced intraocular infiltration of inflammatory cells. Based on these results, we can hypothesize that the proposed PLGA/PCADK microspheres were highly tolerable in ocular tissue and suitable for further application in ocular drug delivery.
In vivo antiangiogenic studies
CAM is widely used for simple studies of the in vivo angiogenic or antiangiogenic activities of drugs in embryonic tissues (Madrigal et al., 2018) . The activity of bevacizumab released from the microspheres was tested. Notably, bevacizumab inhibited the growth of new blood vessels and thus promoted a significant reduction in vascular density. The drug reduced the percentages of blood vessels (relative to the vessels of the negative control) by 53.59% and 49.17% when released from PLGA/ PCADK microspheres and PLGA microspheres, respectively (Fig. 9) . The bevacizumab solution applied at the same concentration led to a reduction of 56.17% in the percentage of blood vessels, similar to the : difference between the negative control group and the other group, outcome of bevacizumab released from the PLGA/PCADK microspheres. The one-way ANOVA showed a significant difference in the percentages of vessels between the positive control group and the PLGA microsphere group (p < 0.05). These data suggested that the drug was more efficient when administered with PLGA/PCADK microspheres compared to PLGA microspheres. This finding proved that the addition of PCADK can better maintain the activity of bevacizumab at a level similar to that of the standard drug solution. The stability of protein drugs mainly refers to the ability to maintain drug biological activity. So we can concluded that this result was implemented with the stability studies described in Section 3.1.
Conclusions
In this study, we used a modified S/O/W emulsion-solvent evaporation technique to prepare bevacizumab-dextran loaded sustainedrelease PLGA/PCADK microspheres after demonstrating the better biocompatibility of bevacizumab with PCADK monomers, compared to PLGA monomers. Compared with microspheres prepared using the W/ O/W method, those prepared using the S/O/W method exhibited uniform drug distribution and improved release behavior, with a minimal initial burst release and a sustained increasing total release. Moreover, PCADK maintained the activity of bevacizumab released from microspheres and induced minimal ocular irritation. These results suggested that bevacizumab-loaded PLGA/PCADK microspheres prepared according to the modified S/O/W method represent a useful approach to intravitreal therapy for ocular diseases.
